In a randomized placebo-controlled trial, vasopressin was associated with decreased blood product use, supporting the need for a bigger trial.
Current dogma for treating trauma patients in shock favors volume repletion over vasopressors. To test whether low-dose arginine vasopressin (AVP) improves outcomes for patients with traumatic hemorrhagic shock, these authors conducted a randomized, double-blind, placebo-controlled study.
During 4 years at a single level-I trauma center, 100 adult trauma patients (aged 18–65 years) who received at least 6 units of any blood product in the initial 12 hours were randomized to AVP or placebo. Patients in the AVP group received an initial bolus of 4 units, followed by a 48-hour infusion of ≤0.04 units/minute, with a target mean arterial pressure of 65 mm Hg.
Among the 100 participants, the total volume of blood products given within 48 hours (the…
Reviewing Author
DisclosuresRoyaltiesUpToDate
Grant/Research SupportEunice Kennedy Shriver National Institute of Child Health and Human Development; MINDSOURCE
Editorial BoardsThe Quarterly Update: Reviews of Current Child Abuse Medical Research; Child Abuse & Neglect: The International Journal
Leadership Positions in Professional SocietiesThe Helfer Society (Executive Committee Member)
DisclosuresRoyaltiesUpToDate
Grant/Research SupportEunice Kennedy Shriver National Institute of Child Health and Human Development; MINDSOURCE
Editorial BoardsThe Quarterly Update: Reviews of Current Child Abuse Medical Research; Child Abuse & Neglect: The International Journal
Leadership Positions in Professional SocietiesThe Helfer Society (Executive Committee Member)